Literature DB >> 23756355

The clinical spectrum of RET proto-oncogene mutations in codon 790.

Hélène Bihan1, Arnaud Murat, Marinos Fysekidis, Abdallah Al-Salameh, Claire Schwartz, Eric Baudin, Philippe Thieblot, Françoise Borson-Chazot, Pierre-Jean Guillausseau, Catherine Cardot-Bauters, Isabelle Raingeard, Elisabeth Requeda, Jean Louis Sadoul, Yves Reznik.   

Abstract

OBJECTIVE: Due to a strong genotype-phenotype correlation, the timing of prophylactic thyroidectomy in rearranged during transfection (RET) gene mutation carriers is usually dictated by genetic analysis. SUBJECTS AND METHODS: We report a nationwide retrospective study of the clinical data of 77 French patients from 19 families with a mutation in codon 790 of the RET proto-oncogene.
RESULTS: The average age at diagnosis was 35.6 years ± 20.5. Thirty-nine patients were women. Fifty-five patients underwent operations for the treatment of medullary thyroid carcinoma (MTC) at the mean age of 38 years (4-82 years). The mean follow-up duration was 89 months. TNM staging was as follows: T0NxMx in 19, TxNxMx in 1, T1NxMx in 22, T1N1Mx in 8, T2N1Mx in 1 and T3N1Mx in four patients. In the T1/x-Nx group, 96% were considered cured after surgery. In the N1 group (n=13), six patients had multifocal disease and five patients were cured. Age and gender were not significant predictors of remission. Twenty-two patients did not undergo an operation (age 1.5-78 years); among them, 11 patients had a mean basal calcitonin (CT) level of 9.8 pg/ml (2-24) after 53 months of follow-up. One patient had been operated on for phaeochromocytoma (PHEO), and their CT level remained normal for 262 months.
CONCLUSIONS: This study confirms that RET 790 mutation is associated with a non-aggressive form of multiple endocrine neoplasia type 2, as 28% of the patients were followed up without thyroidectomy, 25% had been thyroidectomised with no tumour being detected and even patients with MTC had slow-evolving disease. Moreover, only one patient had PHEO, and no-one had primary hyperparathyroidism.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23756355     DOI: 10.1530/EJE-13-0050

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  5 in total

Review 1.  RET revisited: expanding the oncogenic portfolio.

Authors:  Lois M Mulligan
Journal:  Nat Rev Cancer       Date:  2014-03       Impact factor: 60.716

Review 2.  A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma.

Authors:  Cristina Romei; Raffaele Ciampi; Rossella Elisei
Journal:  Nat Rev Endocrinol       Date:  2016-02-12       Impact factor: 43.330

3.  Detection of Molecular Alterations in Medullary Thyroid Carcinoma Using Next-Generation Sequencing: an Institutional Experience.

Authors:  Shuanzeng Wei; Virginia A LiVolsi; Kathleen T Montone; Jennifer J D Morrissette; Zubair W Baloch
Journal:  Endocr Pathol       Date:  2016-12       Impact factor: 3.943

4.  Results and Clinical Interpretation of Germline RET Analysis in a Series of Patients with Medullary Thyroid Carcinoma: The Challenge of the Variants of Uncertain Significance.

Authors:  Giovanni Innella; Cesare Rossi; Maria Romagnoli; Andrea Repaci; Davide Bianchi; Maria Elena Cantarini; Davide Martorana; Lea Godino; Andrea Pession; Antonio Percesepe; Uberto Pagotto; Daniela Turchetti
Journal:  Cancers (Basel)       Date:  2020-11-05       Impact factor: 6.639

5.  Variability in Medullary Thyroid Carcinoma in RET L790F Carriers: A Case Comparison Study of Index Patients.

Authors:  Jes Sloth Mathiesen; Søren Grønlund Nielsen; Åse Krogh Rasmussen; Katalin Kiss; Karin Wadt; Anne Pernille Hermann; Morten Frost Nielsen; Stine Rosenkilde Larsen; Klaus Brusgaard; Anja Lisbeth Frederiksen; Christian Godballe; Maria Rossing
Journal:  Front Endocrinol (Lausanne)       Date:  2020-04-28       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.